aortic valve disease
Conditions
Interventions
TAVR group:N/A
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects must meet all of the following criteria: 1) The subject has guidelines for transcatheter aortic valve replacement surgery (refer to the 2020 American College of Cardiology (ACC)/American Heart Association (AHA) valvular heart disease management guidelines and the 2021 European Society of Cardiology (ESA)/European Association of Cardiothoracic Surgery (EACTS) guidelines for the management of valvular heart disease); 2) Subjects who have been evaluated by the heart team as suitable for the use of transcatheter aortic valve replacement for severe aortic valve disease; 3) The subject or the legal representative of the subject knows the nature of the study, agrees to all the terms of the study, and signs the informed consent approved by the ethics committee of each clinical center; 4) Subjects are willing to complete all clinical follow-ups according to the research requirements.
Exclusion criteria
Exclusion criteria: 1) The subject or the legal representative of the subject is unwilling to sign the informed consent; 2) Subjects are unable to comply with the research protocol and complete all clinical follow-ups due to various reasons; 3) The researcher assesses that the subject is not suitable for transcatheter aortic valve replacement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All cause mortality;The function of biovalve was normal 1 year after operation; | — |
Countries
China
Contacts
Public ContactMao Chen
West China Hospital, Sichuan University
Outcome results
None listed